Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib.

Lung cancer (Amsterdam, Netherlands) - 1 Aug 2014

Robinson Sara D, O'Shaughnessy Joyce A, Cowey C Lance, Konduri Kartik

Abstract excerpt

Somatic BRAF mutations have been reported in 1-4% of non-small cell lung cancer (NSCLC), primarily in adenocarcinomas with the BRAF (V600E) mutation in about 50% of the cases. The role of BRAF mutation in NSCLC and the treatment for tumors with such mutations is still evolving. Our patient had metastatic NSCLC with metastases to her brain. Due to the BRAF (V600E) mutation in her tumor and her poor functional...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma of Lung
Share to Antineoplastic Combined Chemotherapy Protocols

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Biopsy

Share to Indoles

Share to Lymph Nodes

Share to Sulfonamides

Share to Tomography, X-Ray Computed

Share to Vemurafenib

Source

Identifiers

PMID: 24888229
DOI: 10.1016/j.lungcan.2014.05.009

Genes

BRAF

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib.PMID 24888229Read ↗

A patient with BRAF V600E lung adenocarcinoma responding to vemurafenib.Semantic proximity Read ↗

Melanoma brain metastases and vemurafenib: need for further investigation.Semantic proximity Read ↗

BRAFV600 mutant non-small-cell lung cancer resistant to Vemurafenib.Semantic proximity Read ↗

Vemurafenib in patients with BRAF(V600) mutation-positive melanoma with symptomatic brain metastases: final results of an open-label pilot study.Semantic proximity Read ↗

Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study.Semantic proximity Read ↗

BRAF Mutant Pulmonary Melanoma with Brain Metastasis in a Young Female: A Case ReportSemantic proximity Read ↗

BRAFV600E-mutant metastatic NSCLC: disease overview and treatment landscapeSemantic proximity Read ↗

Impact of BRAF mutation and BRAF inhibition on melanoma brain metastases.Semantic proximity Read ↗

Treatment exceeds expectations with vemurafenib monotherapy in a patient with BRAFV600E-mutant metastatic melanoma.Semantic proximity Read ↗

A Retrospective Evaluation of Vemurafenib as Treatment for BRAF-Mutant Melanoma Brain Metastases.Semantic proximity Read ↗

Treatment patterns and outcomes in BRAF V600E-mutant melanoma patients with brain metastases receiving vemurafenib in the real-world setting.Semantic proximity Read ↗

Dramatic response induced by vemurafenib in a BRAF V600E-mutated lung adenocarcinoma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.